Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAMKK2 | Q96RR4 | 3/20 | 0.41 |
| ▸ | FYN | P06241 | 2/20 | 0.38 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.36 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 3/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | GAK | O14976 | 1/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | IGF1R | P08069 | 1/20 | 0.32 |
| ▸ | LCK | P06239 | 1/20 | 0.32 |
| ▸ | TEK | Q02763 | 1/20 | 0.32 |
| ▸ | FEN1 | P39748 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13746535 | 0.94 | CAMKK2 (0.41) | CAMKK2FYNNCOA1NCOA3BRD4 | |
| SCHEMBL13746565 | 0.94 | CAMKK2 (0.39) | CAMKK2FYNBRD4MAOBKDR | |
| SCHEMBL13745719 | 0.93 | CAMKK2 (0.40) | CAMKK2FYNNCOA1NCOA3BRD4 | |
| SCHEMBL13746204 | 0.93 | KDR (0.41) | CAMKK2FYNBRD4GAKMAOB | |
| SCHEMBL13745855 | 0.93 | CAMKK2 (0.36) | CAMKK2FYNBRD4GRM5FFAR4 | |
| SCHEMBL13746271 | 0.92 | CAMKK2 (0.37) | CAMKK2FYNBRD4MAOBLCK | |
| SCHEMBL13745726 | 0.92 | BRD4 (0.37) | CAMKK2FYNNCOA1NCOA3BRD4 | |
| SCHEMBL13746538 | 0.92 | FYN (0.36) | CAMKK2FYNBRD4GRM5MAOB | |
| SCHEMBL13745666 | 0.92 | KDR (0.40) | CAMKK2FYNBRD4MAOBKDR | |
| SCHEMBL13745736 | 0.91 | CAMKK2 (0.55) | CAMKK2FFAR4FEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215771-A1 | JNK INHIBITORS | GRACZYK PIOTR | 2009-08-27 | — | — | US | disclosed |
| US-7432375-B2 | JNK inhibitors | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215771-A1 | JNK INHIBITORS | MAPKAPK2, MAPK1, MAPKAPK3 | CAMKK2 94/4885FYN 259/4885NCOA1 563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.